2. Search Result
Search Result
Results for "

CYP450

" in MedChemExpress (MCE) Product Catalog:

68

Inhibitors & Agonists

3

Peptides

13

Natural
Products

5

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3252A
    Pegcetacoplan acetate
    1 Publications Verification

    		 Complement System Inflammation/Immunology
    Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .
    Pegcetacoplan acetate
  • HY-124527
    HET0016
    5+ Cited Publications

    		 Cytochrome P450 Cardiovascular Disease Cancer
    HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth .
    HET0016
  • HY-12594
    Paritaprevir
    Maximum Cited Publications
    13 Publications Verification

    ABT-450; Veruprevir

    		 HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
    Paritaprevir
  • HY-B0725
    Doxepin Hydrochloride
    5+ Cited Publications

    		 Histamine Receptor Cytochrome P450 Neurological Disease Cancer
    Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .
    . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system .
    . Doxepin has also been proposed as a protective factor against oxidative stress .
    .
    Doxepin Hydrochloride
  • HY-101016
    17-ODYA
    1 Publications Verification

    		 Cytochrome P450 Apoptosis Cardiovascular Disease
    17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes . 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    17-ODYA
  • HY-30152
    Xanthotoxol
    2 Publications Verification

    8-Hydroxypsoralen

    		 5-HT Receptor Reactive Oxygen Species (ROS) Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Xanthotoxol (8-Hydroxypsoralen) It is a kind of fragrant bean substance, and it is a CYP450 inhibitor. Xanthotoxol has anti-inflammatory, anti-inflammatory, and 5-HT antagonistic and protective effects. Xanthotoxol inhibited CYP3A4 sum CYP1A2 IC50s separation 7.43 μM sum 27.82 μM. Xanthotoxol can pass through MAPK and NF-κB, inhibiting inflammation.
    Xanthotoxol
  • HY-Z0056S
    Bromobenzene-d5

    pentadeuterobromobenzene

    		 Cytochrome P450 Endocrinology
    Bromobenzene-d5 is the deuterium labeled Bromobenzene. Bromobenzene is a well-known environmental toxin which causes liver and kidney damage through CYP450-mediated bio-activation to generate reactive metabolites and, consequently, oxidative stress .
    Bromobenzene-d5
  • HY-133091
    7-Ethoxycoumarin

    7-O-Ethylumbelliferone

    		 Cytochrome P450 Metabolic Disease
    7-Ethoxycoumarin is a substrate of cytochrome P450 (CYP450). 7-Ethoxycoumarin has been used for the functional characterization of various CYPs and for the generation of 7-hydroxycoumarin (HY-N0573) .
    7-Ethoxycoumarin
  • HY-B0653A
    Levobupivacaine hydrochloride
    2 Publications Verification

    (S)-(-)-Bupivacaine monohydrochloride

    		 Sodium Channel Ferroptosis Cardiovascular Disease Neurological Disease Cancer
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine hydrochloride
  • HY-108315
    6-Aminochrysene

    6-Chrysenamine

    		 Drug Derivative Inflammation/Immunology Cancer
    6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer. 6-Aminochrysene is activated by CYP450 in rat liver .
    6-Aminochrysene
  • HY-113482
    1β-Hydroxydeoxycholic acid

    1β-OH-DCA

    		 Endogenous Metabolite Cytochrome P450 Metabolic Disease
    1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .
    1β-Hydroxydeoxycholic acid
  • HY-N6023
    Thermopsoside

    		Cytochrome P450 Pregnane X Receptor (PXR) Others
    Thermopsoside is a CYP450 isoenzyme inhibitor and PXR activator. Thermopsoside inhibits CYP3A4, CYP2C19, CYP2D6 and CYP2C9 with IC50 values of 6.0 μM, 9.5 μM, 12.0 μM and 32.0 μM, respectively .
    Thermopsoside
  • HY-N2071
    Cedrol
    1 Publications Verification

    (+)-Cedrol; α-Cedrol

    		 Environmental Pollutants Cytochrome P450 Apoptosis Fungal Caspase Platelet-activating Factor Receptor (PAFR) Infection Neurological Disease Inflammation/Immunology Cancer
    Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties .
    Cedrol
  • HY-N1282
    Seneciphylline

    		Glutathione S-transferase Cytochrome P450 Cancer
    Seneciphylline is an orally effective hepatotoxic inducer. Seneciphylline is metabolized by CYP450 enzymes into active intermediates, which covalently bind to intracellular biomacromolecules such as proteins and DNA to form adducts, which in turn trigger a series of toxic reactions, such as inducing cell apoptosis and damaging mitochondrial function. Seneciphylline can be used in hepatotoxicity research[1][2].
    Seneciphylline
  • HY-113906A
    (αR,8aS)-GSK1614343

    		GHSR Metabolic Disease
    (αR,8aS)-GSK1614343 is the isomer of GSK1614343 (HY-113906). GSK1614343 is the potent antagonist of growth hormone secretagogues type 1a (GHS1a) receptors .
    (αR,8aS)-GSK1614343
  • HY-118607
    VU041

    		Potassium Channel Parasite Infection
    VU041 is a first submicromolar-affinity inhibitor of Anopheles (An.) gambiae and Aedes (Ae.) aegypti inward rectifier potassium 1 (Kir1) channels with IC50 values of 2.5 μM and 1.7 μM, respectively. VU041 inhibits appreciably is mammalian Kir2.1 (IC50 of 12.7 μM), and has less inhibitory effect on mammalian Kir1.1, Kir4.1, Kir6.2/SUR1, and Kir7.1. VU041 also induces impaired Malpighian tubule function .
    VU041
  • HY-10965
    Rolofylline

    KW-3902

    		 Adenosine Receptor Neurological Disease
    Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
    Rolofylline
  • HY-P5542
    Vicatertide

    SB-01; Peniel 2000

    		 Factor Xa TGF-beta/Smad Inflammation/Immunology
    Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a Ka of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .
    Vicatertide
  • HY-W074537
    P7-2104

    		Phosphodiesterase (PDE) Neurological Disease
    P7-2104 is a selective CNS-penetrant PDE7A inhibitor with an IC50 of of 31 nM. P7-2104 exhibits selectivity over hERG channels and most CYP450 isoforms. P7-2104 can be used for PDE7-targeted PET neuroimaging, and for the research of neurodegenerative disorders .
    P7-2104
  • HY-164049
    TG8-260

    		Prostaglandin Receptor Inflammation/Immunology
    TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
    TG8-260
  • HY-131349
    CCR4-351

    		CCR Cancer
    CCR4-351 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity .
    CCR4-351
  • HY-B0653
    Levobupivacaine
    2 Publications Verification

    (S)-(-)-Bupivacaine

    		 Sodium Channel Ferroptosis Neurological Disease Cancer
    Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine
  • HY-B0725S
    Doxepin-d3 hydrochloride

    		Histamine Receptor Cytochrome P450 Neurological Disease
    Doxepin-d3 (hydrochloride) is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 .
    Doxepin-d3 hydrochloride
  • HY-170920
    Herbicide safener-4

    		Cytochrome P450 SOD Glutathione S-transferase Acetolactate Synthase (ALS) Others
    Herbicide safener-4 (Compound I-15) is a Herbicide safener, improving the herbicide resistance of crops without reducing the herbicidal effect on targeted weed species. Herbicide safener-4 competitively binds to the ALS active site with Mesosulfuron-methyl (HY-126987). Herbicide safener-4 enhances GSH (HY-D0187), GST, CYP450, POD, SOD and ALS activity in plants .
    Herbicide safener-4
  • HY-W072025
    CYP2E1-IN-1

    		Cytochrome P450 Keap1-Nrf2 Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Inflammation/Immunology
    CYP2E1-IN-1 (Compound 10) is an orally active cytochrome P450 2E1 (CYP2E1) inhibitor with a Kd of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM. CYP2E1-IN-1 activates the Nrf2/HO-1 signaling pathway and inhibits ROS production, thereby alleviating pancreatic injury. CYP2E1-IN-1 has significant anti-inflammatory and antioxidant activities and can effectively reduce inflammation and oxidative stress in severe acute pancreatitis (SAP). CYP2E1-IN-1 can be used in the study of SAP and other inflammatory-related diseases .
    CYP2E1-IN-1
  • HY-157170
    CYP450-IN-1

    		Cytochrome P450 Cancer
    CYP450-IN-1 (compound 2e) is a potent inhibitor of CYP450 .
    CYP450-IN-1
  • HY-129247
    Versicolorin A

    		MDM-2/p53 Aryl Hydrocarbon Receptor Cytochrome P450 Cancer
    Versicolorin A is a biosynthetic precursor of Aflatoxin B1 (HY-N6615). Versicolorin A induces phosphorylation of p53. Versicolorin A activates the aryl hydrocarbon receptor AhR and significantly induces the expression of CYP1A1. Versicolorin A exerts genotoxic and cytotoxic effects. Versicolorin A enhances the genotoxicity of aflatoxin B1 in cells by promoting CYP450-mediated bioactivation of aflatoxin B1. Versicolorin A can be used in research related to colorectal cancer and hepatocellular carcinoma .
    Versicolorin A
  • HY-N16478
    Echihumiline

    		Cytochrome P450 Metabolic Disease
    Echihumiline is an alkaloid targeting hepatic cytochrome P450 enzymes (CYP450). Echihumiline induces DNA cross-linking and oxidative stress in hepatocytes, leading to liver necrosis and fibrosis. Echihumiline is promising for research of liver diseases .
    Echihumiline
  • HY-115493
    TIQ-15

    		CXCR Others
    TIQ-15 is a potent CXCR4 antagonist with an IC50 value of 6 nM for CXCR4 Ca 2+ flux. TIQ-15 inhibits CYP450 2D6 with an IC50 value of 0.32 μM .
    TIQ-15
  • HY-133091R
    7-Ethoxycoumarin (Standard)

    7-O-Ethylumbelliferone (Standard)

    		 Cytochrome P450 Reference Standards Metabolic Disease
    7-Ethoxycoumarin (Standard) is the analytical standard of 7-Ethoxycoumarin. This product is intended for research and analytical applications. 7-Ethoxycoumarin is a substrate of cytochrome P450 (CYP450). 7-Ethoxycoumarin has been used for the functional characterization of various CYPs and for the generation of 7-hydroxycoumarin (HY-N0573) .
    7-Ethoxycoumarin (Standard)
  • HY-130550
    (±)7(8)-EpDPA

    		Endogenous Metabolite Others
    (±)7(8)-EpDPA is an epoxide derivative of docosahexaenoic acid (DHA) metabolized by CYP450 .
    (±)7(8)-EpDPA
  • HY-131349A
    CCR4-351 hydrochloride

    		CCR Metabolic Disease Cancer
    CCR4-351 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4-351 hydrochloride, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 hydrochloride has antitumor activity .
    CCR4-351 hydrochloride
  • HY-123393
    PNU-142586

    		Topoisomerase Others
    PNU-142586 is the major metabolite of Linezolid (HY-10394). PNU-142586 can inhibit the activity of DNA topoisomerase 2-α (TOP2A) and DNA topoisomerase 2-β (TOP2B). PNU-142586 interferes with DNA replication and transcription by blocking the binding of DNA to TOP2 and inhibiting ATP hydrolysis, ultimately leading to antiproliferative and cytotoxic effects, including mitochondrial dysfunction. PNU-142586 can be used to study Linezolid-induced hematotoxicity and its molecular mechanism .
    PNU-142586
  • HY-153671
    4'-Methyl-β-naphthoflavone

    		Fungal Infection
    4'-Methyl-β-naphthoflavone is a metabolite of Naphthoflavones (benzoflavones) in fungal. Naphthoflavones are activators or inhibitors of CYP-450 .
    4'-Methyl-β-naphthoflavone
  • HY-145546
    14(15)-EpETE

    		Cytochrome P450 Metabolic Disease
    14(15)-EpETE is the epoxide of cytochrome P450 (CYP450) and is involved in the regulation of vascular tone and renal function .
    14(15)-EpETE
  • HY-133091S
    7-Ethoxycoumarin-d5

    		Cytochrome P450 Isotope-Labeled Compounds Others
    7-Ethoxycoumarin-d5 is deuterium labeled 7-Ethoxycoumarin. 7-Ethoxycoumarin is a substrate for cytochrome P450(CYP450) and has been used in the functional characterization of various CYPs .
    7-Ethoxycoumarin-d5
  • HY-130219
    18-HETE

    		Endogenous Metabolite Others
    18-HETE (compound 3) is a monooxygenase metabolite of cytochrome P450 (CYP450).18- HETE consists of arachidonic acid bearing a hydroxy substituent at position 18 .
    18-HETE
  • HY-B0725R
    Doxepin Hydrochloride (Standard)

    		Reference Standards Histamine Receptor Cytochrome P450 Neurological Disease Cancer
    Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .
    . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system .
    . Doxepin has also been proposed as a protective factor against oxidative stress .
    .
    Doxepin Hydrochloride (Standard)
  • HY-W803860
    N-Depropylpropafenone

    		Drug Metabolite Sodium Channel Cardiovascular Disease
    N-Depropylpropafenone is an active metabolite of Propafenone (HY-B0432), generated through the CYP450 enzyme system (mainly CYP2D6). It functions by blocking sodium ion channels, slowing myocardial conduction and exhibiting certain antiarrhythmic effects .
    N-Depropylpropafenone
  • HY-124527R
    HET0016 (Standard)

    		Cytochrome P450 Cardiovascular Disease Cancer
    HET0016 (Standard) is the analytical standard of HET0016. This product is intended for research and analytical applications. HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth .
    HET0016 (Standard)
  • HY-178479
    IDO1-IN-30

    		Indoleamine 2,3-Dioxygenase (IDO) Cytochrome P450 Inflammation/Immunology Cancer
    IDO1-IN-30 (Compound (R)-100) is a potent and highly selective IDO1 inhibitor. IDO1-IN-30 has an IC50 of 4.8 nM to IDO1 in SKOV3 cells. IDO1-IN-30 does not show significant cytotoxicity at 25 µM in HepG2 cells. IDO1-IN-30 can eliminate inhibition of CYP450 enzymes (such as 3A4, 2C9, 2D6). IDO1-IN-30 can be used for research on cancer and inflammatory conditions .
    IDO1-IN-30
  • HY-12594A
    Paritaprevir dihydrate

    ABT-450 dihydrate; Veruprevir dihydrate

    		 HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .
    Paritaprevir dihydrate
  • HY-12594R
    Paritaprevir (Standard)

    ABT-450 (Standard); Veruprevir (Standard)

    		 HCV Protease HCV SARS-CoV Reference Standards Infection
    Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
    Paritaprevir (Standard)
  • HY-130309
    (±)8(9)-EpETE

    (±)8,9-EEQ; (±)8,9-epoxy Eicosatetraenoic acid

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Eicosapentaenoic acid (EPA) is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. The major product of this epoxygenase pathway, (±)17(18)-EpETE, relaxes vascular and airway smooth muscle by activating large conductance Ca 2+-activated K + (BKCa) channels by directly interacting with BKα channel subunits. (±)8(9)-EpETE is an epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo.
    (±)8(9)-EpETE
  • HY-30152R
    Xanthotoxol (Standard)

    8-Hydroxypsoralen (Standard)

    		 Reference Standards 5-HT Receptor Reactive Oxygen Species (ROS) Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Xanthotoxol (Standard) is the analytical standard of Xanthotoxol. This product is intended for research and analytical applications. Xanthotoxol (8-Hydroxypsoralen) It is a kind of fragrant bean substance, and it is a CYP450 inhibitor. Xanthotoxol has anti-inflammatory, anti-inflammatory, and 5-HT antagonistic and protective effects. Xanthotoxol inhibited CYP3A4 sum CYP1A2 IC50s separation 7.43 μM sum 27.82 μM. Xanthotoxol can pass through MAPK and NF-κB, inhibiting inflammation .
    Xanthotoxol (Standard)
  • HY-165060
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol

    (±)2-14,15-EG

    		 DNA/RNA Synthesis Metabolic Disease
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol ((±)2-14,15-EG) is a novel CYP450 metabolite of 2-Arachidonoyl glycerol (2-AG) in the kidney. (±)2-(14,15-Epoxyeicosatrienoyl) glycerol is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells. (±)2-(14,15-Epoxyeicosatrienoyl) glycerol activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway .
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol
  • HY-126751
    DBM-819

    		Na+/K+ ATPase Metabolic Disease
    DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H +/K +-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research .
    DBM-819
  • HY-10965R
    Rolofylline (Standard)

    KW-3902 (Standard)

    		 Adenosine Receptor Reference Standards Neurological Disease
    Rolofylline (Standard) is the analytical standard of Rolofylline. This product is intended for research and analytical applications. Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
    Rolofylline (Standard)
  • HY-101016R
    17-ODYA (Standard)

    		Reference Standards Cytochrome P450 Apoptosis Cardiovascular Disease
    17-ODYA (Standard) is the analytical standard of 17-ODYA. This product is intended for research and analytical applications. 17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes[1][2][3]. 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    17-ODYA (Standard)
  • HY-B0653AS
    Levobupivacaine-d9 hydrochloride

    (S)-(–)-Bupivacaie-d9hydrochloride

    		 Isotope-Labeled Compounds Ferroptosis Sodium Channel Cardiovascular Disease Neurological Disease Cancer
    Levobupivacaine-d9 ((S)-(–)-Bupivacaie-d9) hydrochloride is deuterium labeled Levobupivacaine hydrochloride (HY-B0653A). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine-d9 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: